Regulatory Exclusivity Expiring in 2027
✉ Email this page to a colleague
Drugs with Regulatory Exclusivity Expiring in 2027
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Exclusivity Expiration | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Ucb Inc | FINTEPLA | fenfluramine hydrochloride | SOLUTION;ORAL | 212102-001 | Jun 25, 2020 | RX | Yes | Yes | ⤷ Get Started Free | PEDIATRIC EXCLUSIVITY | |
| Polarean | XENOVIEW | xenon xe-129 hyperpolarized | GAS;INHALATION | 214375-001 | Dec 23, 2022 | RX | Yes | Yes | ⤷ Get Started Free | NEW CHEMICAL ENTITY | |
| Gilead Sciences Inc | SUNLENCA | lenacapavir sodium | SOLUTION;SUBCUTANEOUS | 215973-001 | Dec 22, 2022 | RX | Yes | Yes | ⤷ Get Started Free | NEW CHEMICAL ENTITY | |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Exclusivity Expiration | >Patented / Exclusive Use |
